I am Sid Labed, Founder and CEO of EvoDenovo, building the next generation of antidepressant therapeutics with a clear objective: deliver clinically meaningful improvement for patients on timelines that matter, and raise the standard for care in mental health.
My work sits at the intersection of neuroimmunology, translational science, and company building. I have a PhD in Immunology (University of Aix-Marseille) and eight years of postdoctoral training at Harvard Medical School, where I focused on neuro-immune biology relevant to psychiatric disease. I apply that rigor to therapeutic development with an execution mindset, aligning mechanism, translational evidence, and development strategy to support capital-efficient progress.
As CEO, I lead strategy, fundraising, and external partnerships, and I work closely with scientific and clinical collaborators to translate biology into credible, investable development programs in depression and mental health.

I engage with:
Strategic and venture investors focused on CNS and mental health innovation
Pharma BD and R&D leaders exploring collaboration, licensing, or co-development in antidepressants
Clinical investigators and academic groups for translational research, biomarkers, and trial execution
Ecosystem partners supporting clinical operations, regulatory strategy, and development enablement
If you are focused on advancing transformative antidepressant therapies and building high-impact mental health solutions, I welcome a direct conversation.

Let’s innovate and make a difference together!